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Persistence of cognitive impairment and its
negative impact on psychosocial functioning in
lithium-treated, euthymic bipolar patients: a 6-year
follow-up study
E. Mora1, M. J. Portella2, I. Forcada1, E. Vieta3 and M. Mur1*
1 Psychiatric Service, Hospital Santa Maria, University of Lleida, IRBLleida (Biomedicine Research Institute), Lleida, Spain
2 Psychiatric Service, Research Institute, Hospital de Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
3 Bipolar Disorders Program, Hospital Clı´nic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
Background. Previous cross-sectional studies report that cognitive impairment is associated with poor psychosocial
functioning in euthymic bipolar patients. There is a lack of long-term studies to determine the course of cognitive
impairment and its impact on functional outcome.
Method. A total of 54 subjects were assessed at baseline and 6 years later ; 28 had DSM-IV TR bipolar I or II disorder
(recruited, at baseline, from a Lithium Clinic Program) and 26 were healthy matched controls. They were all assessed
with a cognitive battery tapping into the main cognitive domains (executive function, attention, processing speed,
verbal memory and visual memory) twice over a 6-year follow-up period. All patients were euthymic (Hamilton
Rating Scale for Depression score lower than 8 and Young mania rating scale score lower than 6) for at least 3 months
before both evaluations. At the end of follow-up, psychosocial functioning was also evaluated by means of the
Functioning Assessment Short Test.
Results. Repeated-measures multivariate analysis of covariance showed that there were main eﬀects of group in the
executive domain, in the inhibition domain, in the processing speed domain, and in the verbal memory domain
(p<0.04). Among the clinical factors, only longer illness duration was signiﬁcantly related to slow processing
(p=0.01), whereas strong relationships were observed between impoverished cognition along time and poorer
psychosocial functioning (p<0.05).
Conclusions. Executive functioning, inhibition, processing speed and verbal memory were impaired in euthymic
bipolar out-patients. Although cognitive deﬁcits remained stable on average throughout the follow-up, they had
enduring negative eﬀects on psychosocial adaptation of patients.
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Introduction
A considerable amount of evidence has conﬁrmed that
neuropsychological functioning is impaired in in-
dividuals with bipolar disorder, not only during acute
episodes but also during periods of remission of af-
fective symptoms, namely euthymic states (Torres
et al. 2007). Despite current evidence, the neuro-
psychological proﬁle during euthymia has not yet
been well established and substantial heterogeneity
has been reported (Mann-Wrobel et al. 2011).
Emerging data suggest that patients with bipolar
disorder exhibit cognitive impairment in attention,
verbal memory and executive functioning during
remission (Martı´nez-Ara´n et al. 2004b ; Mur et al. 2007;
Torres et al. 2007 ; Mann-Wrobel et al. 2011). Several
studies reveal that it is important to examine cognitive
performance in euthymic bipolar disorder patients
since there is a strong association between neuro-
psychological impairment and poor psychosocial
functioning outcome (Wingo et al. 2009).
Most of the previous studies on neurocognition and
its functional impact in euthymic patients are cross-
sectional. Since bipolar disorder is a chronic and re-
current disease it is necessary to proceed examining
longitudinally the cognitive and functional course of
these individuals in order to clarify the particular
nature and speciﬁcity of the reported deﬁcits and how
these can change over time (Robinson & Ferrier, 2006).
There is an actual lack of longitudinal studies in
the current literature foreclosing the possibility to
* Address for correspondence : M. Mur, M.D., Ph.D., Servei
de Psiquiatria, Hospital Santa Maria, C/Rovira Roure, 44, 25198
Lleida, Catalunya, Spain.
(Email : mmur@gss.scs.es)
Psychological Medicine (2013), 43, 1187–1196. f Cambridge University Press 2012
doi:10.1017/S0033291712001948
ORIGINAL ARTICLE
determine the evolution of cognition (Balanza´-
Martı´nez et al. 2005 ; Burdick et al. 2006 ; Mur et al. 2008 ;
Tabare´s-Seisdedos et al. 2008) and psychosocial func-
tioning (Martino et al. 2009 ; Bonnı´n et al. 2010 ; Burdick
et al. 2010) in euthymic bipolar patients. Furthermore,
the cognitive follow-up of these patients becomes
crucial for providing tools to administer the most
suitable pharmacological and psychosocial treatment
strategies (Gildengers et al. 2009).
The aim of the present study is to investigate the
longitudinal neuropsychological proﬁle of euthymic
bipolar out-patients compared with healthy matched
controls in a 6-year period of follow-up and to exam-
ine the psychosocial disabilities as related to cognitive
deﬁcits. An important methodological feature of
this study, as compared with the very few previous
studies that looked at this issue, is that healthy control
subjects were also assessed at baseline and 6 years
later, controlling for the eﬀects of time and ageing. We
hypothesized that the cognitive deﬁcits would remain
stable regardless of the clinical course of the illness,
and this impairment would be related to the psycho-
social adaptation at the end of the follow-up.
Method
Subjects
A total of 28 euthymic bipolar patients and 26 healthy
matched controls were admitted into the study and
were evaluated at baseline and 6 years later with a
clinical interview, biochemical tests and a neuro-
psychological battery. On average, the endpoint (T2)
occurred 6.1 years after baseline (T1) (range 8.2–4.9
years) and was conducted by the same neuropsychol-
ogist. The Local Ethics Committee approved the study,
and written informed consent was obtained from all
participants (patients and healthy controls).
The patient sample was obtained from the Lithium
Clinic Program at Hospital Santa Maria, Lleida, in
2003. Inclusion criteria included being on lithium
treatment at T1, aged between 18 and 65 years, fulﬁl-
ling Diagnostic and Statistical Manual of Mental
Disorders, fourth edition, text revision (DSM-IV-TR)
criteria for bipolar disorder, and being in remission for
at least 3 months (Mur et al. 2007). Following previous
studies (Robinson et al. 2006), patients were charac-
terized as euthymic if they had a total 17-item
Hamilton Rating Scale for Depression (HAMD;
Hamilton, 1960) score below 8 and a total Young
Mania Rating Scale (YMRS; Young et al. 1978) score
below 6 for at least 3 months at the time of assessment.
Exclusion criteria were the following: signiﬁcant
physical or neurological illness, substance abuse or
dependence in the last 12 months, electroconvulsive
therapy in the preceding year. At the endpoint,
patients had to fulﬁl the same inclusion and exclusion
criteria, except for medication that was allowed to be
changed during the 6 years, if clinically needed.
Therefore, at follow-up, all subjects were retested if
they had been euthymic for at least 3 months, as con-
ﬁrmed by the criteria as at baseline.
A total of 26 healthy controls from the same geo-
graphic area, matched in terms of gender, age and
years of education were recruited via advertisements
and from non-medical hospital staﬀ. Controls had no
current or past psychiatric history, as determined by
the Structured Clinical Interview for DSM-IV Axis I
Disorders. They had no ﬁrst-degree relatives with bi-
polar or psychotic diagnoses. Controls were subject to
the same exclusion criteria and were assessed with the
same full study protocol as the patients. They were
also evaluated twice (at baseline and 6 years later).
Demographic, clinical and pharmacological data
Demographic variables for euthymic bipolar patients
and healthy controls were age, gender, years of edu-
cation and family history of mental illness. Clinical
variables were obtained from the sample of bipolar
patients, including: age at illness onset, number of
prior manic episodes and hospitalizations, period of
stabilization (years), history of psychotic symptoms,
seasonal pattern, suicide attempts and bipolar subtype
(I or II). Biochemical tests were performed on all pa-
tients, including for thyroid function, serum lithium
levels and urine drug testing.
With respect to pharmacological variables, at base-
line, T1, 14 patients were receiving lithium as mono-
therapy and the other 14 were on combination
treatment (lithium plus antidepressants and/or anti-
psychotics). Lithium dosages at T1 were 820–
1380 mg/day (serum lithium levels 0.46–0.86 mmol/l ;
treatment duration 1–10 years). At the study endpoint,
T2, two patients were drug-free, 10 were receiving
lithium monotherapy, 11 were on combination treat-
ment (lithium dosage 916–1388 mg/day; serum lith-
ium levels 0.51–0.71 mmol/l ; treatment duration 5–15
years) ; and ﬁve were receiving other psychopharma-
cological treatments (two were receiving other mood
stabilizers, one was on a combination of anti-
depressant and antipsychotic, another one was re-
ceiving another mood stabilizer plus antidepressant
and the other was on another mood stabilizer plus
antipsychotic).
Neuropsychological assessment
To provide a more general pattern of cognitive per-
formance, this battery included neuropsychological
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tests that tapped into broad cognitive categories as
documented in previous literature (Mur et al. 2007). The
estimated mean intelligence quotient (IQ) of the sub-
jects was obtained from the weighted scores of the
Vocabulary and Block Design subtests of the Wechsler
Adult Intelligence Scale (WAIS-III ; Wechsler, 2001),
because these two scores are the most highly correlated
with total IQ. The instruments administered were:
(i) Vocabulary, Block Design and Digits Subtests
from WAIS-III (Wechsler, 2001) ;
(ii) Wisconsin Card Sorting Test (WCST; Heaton,
1981) ;
(iii) Stroop Colour andWord Test (Spreen & Strauss,
1998) ;
(iv) Verbal ﬂuency task of the Controlled Oral Word
Association Test/Categories (FAS; Spreen &
Strauss, 1998) ;
(v) Trail Making Test (TMT), part A (TMT-A) and
part B (TMT-B) (Reitan, 1958) ;
(vi) Conners’ Continuous Performance Test II (CPT-
II ; Conners, 2000) ;
(vii) California Verbal Learning Test (CVLT; Delis
et al. 1987) ;
(viii) Rey Complex Figure Test (RCFT; Meyers &
Meyers, 1995).
Psychosocial functioning
At baseline, to obtain information about global ac-
tivity, patients and controls were assessed with the
Global Assessment of Functioning scale. Moreover,
occupational functioning was speciﬁcally assessed
and deﬁned as follows: active (subjects with a full- or
part-time job, students and housewives), inactive
(unemployed subjects and those with temporary sick
leave) and retired (permanent sick leave or retired
subjects). At the endpoint, another scale was also ad-
ministered in order to evaluate psychosocial func-
tioning more accurately. The Functioning Assessment
Short Test (FAST; Rosa et al. 2007) is more appropriate
since it takes into consideration diﬀerent domains and
it is more speciﬁc for assessing diﬀerent levels of
functioning in bipolar disorder. Its 24 items of the scale
are divided into six speciﬁc areas of functioning:
autonomy, occupational functioning, cognitive func-
tioning, ﬁnancial issues, interpersonal relationships
and leisure time. Therefore, subscores can be obtained
from these areas as well as a total score.
Statistical procedures
Data analyses were carried out with the statistical
package SPSS for Windows, version 15.0 (SPSS Inc.,
USA). Diﬀerences between groups in demographic,
psychosocial and clinical variables were assessed with
a univariate analysis of variance, by examining a
single factor of group (out-patients versus healthy
controls) at T1 and at T2; and paired two-sample
t tests were used to assess time diﬀerences for such
variables. Non-quantitative variables were examined
by means of non-parametric tests.
Neuropsychological tasks were sorted by cognitive
domains : executive functions, attention, processing
speed, verbal memory and visual memory (Mur et al.
2008). Performance on neuropsychological tasks was
compared across the two groups by means of separate
multivariate repeated-measures analyses of covariance
(MANCOVA) for each cognitive domain. Estimated
pre-morbid IQ, YMRS and HAMD scores were in-
cluded as covariates since they showed signiﬁcant dif-
ferences between groups at T2, as shown in Table 2.
The cognitive variables that did not meet the criterion
of normality were excluded from the multivariate
analyses : CVLT recognition, number of perseverative
errors at CPT-II and number of categories ofWCST. No
other analyses were carried out with these latter vari-
ables as the cognitive domains were already suﬃ-
ciently explored with other neuropsychological tests.
In order to establish correlations between cognitive
changes in neuropsychological performance after 6
years in bipolar patients with clinical and functional
variables, the diﬀerence between scores at T2 and T1
was calculated for those variables that showed sig-
niﬁcant diﬀerences between groups. Therefore new
variables that reﬂected performance decrement or in-
crement across time were obtained (DDigit backward,
DTMT-B, DTMT-A, DCVLT immediate recall, DCVLT
delayed recall, DStroop Inhibition and DHit Reaction
Time in CPT-II). Then, associations between cognitive
changes and clinical and functional variables were
analysed with partial correlations by controlling for
low-level depressive symptoms (HAMD) as shown in
Table 3.
Results
Demographic, clinical and functional results
Demographic, clinical and pharmacological variables
of the euthymic bipolar patients and healthy controls
are displayed in Table 1 for the two time points
(T1 and T2). Both groups of participants were matched
in terms of age and gender. At T1, estimated pre-
morbid IQ showed diﬀerences between the groups
(F1,52=10.06, p=0.003) although it was not clinically
relevant as all scores were situated within the range of
100¡15, not exceeding the limits of normality. In
terms of work status, the groups displayed signiﬁcant
diﬀerences [x2=8.4, degrees of freedom (df)=1,
Persistence of cognitive impairment in bipolar patients 1189
p=0.004] ; the bipolar patients were less active and
more retired than the healthy controls. With regard to
subclinical symptomatology, YMRS score also diﬀered
between the two groups (F1,52=6.24, p=0.016), but
HAMD score did not diﬀer (F1,52=0.36, p>0.05). At T2,
6 years later, the bipolar euthymic patients and
healthy controls also diﬀered in estimated IQ
(F1,52=8.52, p=0.005) and work status (x2=7.4, df=1,
p=0.006). On this occasion, they diﬀered in HAMD
score (F1,52=9.24, p=0.004), but not in YMRS score
(F1,52=2.49, p>0.05). None of the participants showed
any evidence of clinical abnormality as checked with
biochemical tests.
The group of bipolar patients exhibited signiﬁcant
worsening along the 6-year follow-up in their work
status (x2=11.3, df=1, p=0.001) and in subsyndromal
depressive symptoms, measured by HAMD score
(t=0.45, p=0.016). At the endpoint, illness duration
was of 24 years and patients had been stable for 7
years on average. However, during the study period
12 out of 28 patients (42.9%) suﬀered relapses : six
patients (21.4%) suﬀered one or two episodes and the
rest (21.4%) suﬀered more than two episodes. These
episodes were clinically characterized as follows : 16
were depressive, seven mixed, 10 manic and two
hypomanic.
Neuropsychological performance
All neuropsychological variables included in each
cognitive domain are listed in Table 2. As can be
observed, after controlling for estimated pre-morbid
Table 1. Demographic, clinical and pharmacological variables at T1 and T2
Variable
Bipolar patients (n=28) Healthy controls (n=26)
T1 T2 T1 T2
Mean age, years (S.D.) 41.71 (12.4) 46.71 (13) 41.38 (12.1) 47.81 (12.2)
Mean years of education (S.D.) 10.1 (2.5) 10.1 (2.5) 12.2 (3.3) 12.5 (3.2)
Mean estimated pre-morbid IQ (S.D.) 97.8 (11.8) 102.2 (12.3) 107.3 (10.2) 111.1 (9.7)
Mean YMRS score (S.D.) 1.64 (1.9) 1 (1.3) 0.62 (0.9) 0.5 (1)
Mean HAMD score (S.D.) 1.46 (1.7) 2.11 (2.2) 1.23 (1.1) 0.62 (1.2)
Mean GAF score (S.D.) 72.32 (10.1) 72.86 (9.7) 92.4 (3.9)
Mean age at onset, years (S.D.) 22.39 (9.4) 22.39 (9.4)
Mean number of hospitalizations (S.D.) 3.04 (2.4) 3.64 (2.9)
Mean total number of manic episodes (S.D.) 2.54 (2.1) 3.14 (2.9)
Mean years of stabilization (S.D.) 3.18 (3.2) 7.11 (5.2)
Mean duration of illness, years (S.D.) 18.43 (13.5) 24.29 (13.5)
Mean years of lithium treatment (S.D.) 5.33 (4.4) 10 (4.9)
Mean serum lithium levels, mmol/l (S.D.) 0.66 (0.2) 0.71 (0.2)/21
Mean lithium dosage, mg/d (S.D.) 1100 (280) 1152 (236)/21
Gender, number of males (%) 14 (50) 12 (46.2)
Current work status, n (%)
Active 14 (50) 13 (46.4) 23 (88.5) 22 (84.6)
Inactive 4 (14.3) 2 (7.2) 1 (3.8) 0
Retired/disabled 10 (35.7) 13 (46.4) 2 (7.7) 4 (15.4)
Positive family history of mental illness, n (%) 21 (75) 21 (75) 6 (23.1) 6 (23.1)
Lifetime history of psychotic symptoms, n (%) 22 (78.6) 22 (78.6)
Lifetime history of seasonal pattern, n (%) 17 (60.7) 17 (60.7)
Personal history of suicide attempts, n (%) 14 (50) 16 (57.1)
Diagnosis, n (%)
Bipolar I disorder 19 (67.9) 19 (67.9)
Bipolar II disorder 9 (32.1) 9 (32.1)
Type of current medication, n (%)
Lithium monotherapy 14 (50) 10 (35.7)
Lithium+combination 14 (50) 11 (39.3)
Others 5 (17.9)
None 2 (7.1)
T1, Baseline ; T2, 6-year endpoint ; S.D., standard deviation ; IQ, intelligence quotient ; YMRS, Young Mania Rating Scale ;
HAMD, Hamilton Rating Scale for Depression ; GAF, Global Assessment of Functioning.
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IQ, the repeated-measures MANCOVA showed no
signiﬁcant interactions of time (T1 versus T2) by group
(patients versus healthy controls) except in the verbal
memory domain. By contrast, there were main eﬀects
of group in the executive domain (TMT-B and digit
span backward), in the inhibition domain (Stroop in-
hibition), in the processing speed domain (TMT-A and
hit reaction time of CPT-II), and ﬁnally in the verbal
memory domain (immediate and delayed recall).
Since previous studies (Clark et al. 2002 ; Martı´nez-
Ara´n et al. 2004a ; Savitz et al. 2005 ; Kurtz & Gerraty,
2009) have already established the impact of residual
mood symptoms, a repeated-measures MANCOVA
was also performed, controlling for pre-morbid IQ and
by YMRS and HAMD score. Even including these
covariates, the results showed again the same eﬀects,
except for the interaction in the hit reaction time of
CPT-II (although it depicted a similar trend), which
did not reach the signiﬁcance threshold. Signiﬁcant
group eﬀects are presented in Fig. 1. Given that ﬁve
patients were not on lithium treatment at T2, data
were reanalysed excluding those individuals and the
results were statistically similar to the whole sample
results (data not shown) which might indicate that
even when the medication regimen is less homo-
geneous, cognitive performance is statistically equiv-
alent.
Association results
Relationships between cognitive impairment across
time and clinical and functional variables in bipolar
Table 2. Neuropsychological results at T1 and T2 for all participants
Test
Bipolar patients Healthy controls Statistical analysis
T1 T2 T1 T2 F df pa pb
Executive test 1.96c 3,42 N.S. N.S.
TMT part B 82.96 (27.7) 102.7 (50.1) 55.9 (22.1) 55.7 (20.0) 7.1d 1,44 0.006 0.008
FAS 38.1 (12.2) 37.0 (12.8) 44.1 (9.4) 43.7 (10.1) 0.8d 1,44 N.S. N.S.
WAIS-III digit span backward 5.1 (1.7) 4.9 (1.8) 6.5 (1.9) 6.6 (1.6) 7.0d 1,44 0.008 0.012
Inhibition 0.46c 2,46 N.S. N.S.
Stroop inhibition 35.93 (10.9) 33.93 (12.4) 44.32 (6.2) 43.18 (8.2) 7.82d 1,47 0.004 0.011
No. of perseverative errors WCST 26.68 (21.1) 21.71 (14.5) 18.27 (12.7) 11.73 (11.1) 2.05d 1,47 N.S. N.S.
Attention 2.6c 3,45 N.S. N.S.
Stroop interference x0.70 (6.6) 1.11 (7.7) 0.82 (4.7) 3.9 (7.8) 0.95d 1,47 N.S. N.S.
WAIS-III digit span forward 7.5 (1.9) 7.5 (1.8) 8.9 (2) 8.6 (2.1) 2.80d 1,47 N.S. N.S.
CPT-II detectability, d’ 0.97 (0.5) 0.87 (0.4) 0.87 (0.5) 1.1 (0.4) 0.08d 1,47 N.S. N.S.
Processing speed 0.27c 2,46 N.S. N.S.
TMT part A, ms 45.89 (21.5) 47.75 (22.23) 29.73 (16.5) 28.23 (10.5) 6.54d 1,47 0.009 0.030
CPT-II hit reaction time, ms 474.2 (75.6) 492.8 (112) 423.6 (68.1) 425.4 (66.3) 6.52d 1,47 0.022 N.S. 0.079
Verbal memory 4.53c 4,44 0.024 0.049
CVLT ﬁrst trial 6.75 (1.8) 6.11 (2) 6.55 (1.3) 7.59 (1.9) 0.88d 1,47 N.S. N.S.
CVLT total words 51.5 (10) 49.36 (12.1) 54.86 (5.8) 57.68 (7.3) 3.59d 1,47 N.S. 0.052 N.S.
CVLT immediate recall 10.68 (2.7) 10.64 (3.1) 11.5 (2.2) 13.45 (1.6) 5.26d 1,47 0.008 0.013
CVLT delayed recall 11.07 (2.5) 11.21 (3.1) 12.32 (2.1) 14.09 (1.5) 6.57d 1,47 0.009 0.028
Visual memory 1.39c 2,44 N.S. N.S.
RCFT immediate recall 19.33 (6.6) 19.6 (6) 23.34 (4.7) 23.41 (4.6) 4.19d 1,45 N.S. N.S.
RCFT delayed recall 18.38 (6.1) 20.71 (6.2) 22.7 (5.2) 23.3 (5.4) 1.88d 1,45 N.S. N.S.
Data are given as mean (standard deviation).
T1, Baseline ; T2, 6-year endpoint ; df, degrees of freedom; N.S., not signiﬁcant ; TMT, Trail Making Test ; FAS, verbal ﬂuency task of
the Controlled Oral Word Association Test ; WAIS-III, Wechsler Adult Intelligence Scale-III ; WCST, Wisconsin Card Sorting Test ;
CPT-II, Continuous Performance Test II ; CVLT, California Verbal Learning Test ; RCFT, Rey Complex Figure Test ; MANCOVA,
multivariate repeated-measures analyses of covariance ; IQ, intelligence quotient ; HAMD, Hamilton Rating Scale for Depression ;
YMRS, Young Mania Rating Scale.
a Probability of repeated-measures MANCOVA controlling for IQ.
b Probability of repeated-measures MANCOVA controlling for IQ, HAMD and YMRS.
c Repeated-measures MANCOVA multivariate eﬀects for each cognitive domain (grouprtime interactions).
d Repeated-measures MANCOVA main eﬀects of group (test of between-subjects eﬀects).
Persistence of cognitive impairment in bipolar patients 1191
patients can be seen in Table 3. Clinical characteristics
at the endpoint were not related to a worsening in
neuropsychological results, with the exception of
duration of illness that showed a signiﬁcant corre-
lation with hit reaction time of CPT-II (p=0.01). In
respect of FAST total score, partial correlations dis-
played strong relationships between poorer psy-
chosocial functioning and a worsening of cognition.
Interestingly, some of the neuropsychological tests
(TMT-B, hit reaction time of CPT-II, immediate and
delayed recall of CLVT and Stroop inhibition) that
were more impaired at T2 also correlated with worse
cognitive and occupational areas and total score of the
FAST.
Discussion
The present ﬁndings show that the cognitive func-
tioning of euthymic bipolar patients remains, on av-
erage, steadily aﬀected in 6 years of follow-up.
Interestingly, psychosocial impairment was more evi-
dent in those patients showing a neuropsychological
decline. The cognitive domains found to be aﬀected in
the present study (executive functioning, inhibition,
processing speed and verbal memory) are in congru-
ence with the reported data in recent meta-analyses
(Robinson et al. 2006 ; Torres et al. 2007; Mur et al. 2008 ;
Arts et al. 2008 ; Bora et al. 2009 ; Kurtz & Gerraty, 2009).
Furthermore, our results indicate that these particular
cognitive domains are linked with psychosocial func-
tioning.
As has already been mentioned, there are very few
data regarding follow-up studies on neurocognition in
bipolar disorder (Robinson & Ferrier, 2006; Mann-
Wrobel et al. 2011). Our investigation had a unique
design because the cognitive performance was as-
sessed at two time points in a 6-year period of follow-
up in euthymic bipolar patients and in the same
healthy controls. Indeed, only ﬁve longitudinal studies
on bipolar disorder and neurocognition have
been published so far. Among these previous studies,
four of them detected persistent cognitive impairment
along time (Engelsmann et al. 1988 ; Balanza´-Martı´nez
et al. 2005 ; Mur et al. 2008 ; Tabare´s-Seisdedos
et al. 2008), whereas one of them (Burdick et al. 2006)
reported that executive and memory functioning
suﬀered more variations over time.
In the present study, extending the re-examination
until 6 years has demonstrated that cognitive dys-
function persists even during longer periods of clinical
remission. What is more relevant, however, is that the
changes in cognitive performance in 6 years aﬀect di-
rectly the psychosocial adaptation of these patients as
observed in the correlations with the FAST (Rosa et al.
2007). In particular, the areas that appear to be as-
sociated with the neuropsychological changes were
the cognitive and occupational areas of the FAST. This
latter area deserves a comment, since patients with
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Fig. 1. Neuropsychological performance of the two groups (patients and healthy controls) at two time points (baseline and
6-year endpoint) for those tests that showed group eﬀects in the multivariate repeated-measures analyses. Raw scores were
transformed into t scores from normative data for adult subjects. Transformation makes the comparison among tests more easily
understandable. TMT, Trail Making Test ; CPT-II, Continuous Performance Test II ; RT, reaction time ; CVLT, California Verbal
Learning Test.
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bipolar disorder tend to have high rates of unem-
ployment (Dean et al. 2004 ; Mur et al. 2009), and it may
reﬂect the impact of the disorder on the psychosocial
adaptation of patients. In this regard, previous studies
have reported that unemployment would be particu-
larly impaired in those with processing speed deﬁcits
(Mur et al. 2008) or with attention deﬁcits (O’Shea et al.
2010).
Previous longitudinal studies evaluating clinical
and neurocognitive predictors of functional outcome
by means of the FAST (Martino et al. 2009 ; Bonnı´n et al.
2010) or other scales (Burdick et al. 2010) have dem-
onstrated the strong relationship of neuropsychologi-
cal performance and the daily functioning of patients.
The cognitive variables that appeared to be related
with poor functional outcome were processing speed
(Burdick et al. 2010), verbal memory and executive
functions (Bonnı´n et al. 2010), and verbal memory and
attention (Martino et al. 2009). However, the neuro-
psychological performance of patients in these studies
was obtained only once, andwas used as a predictor of
psychosocial adaptation, so the actual impact of cogni-
tive changes on functioning could not be evaluated.
This present study suggests that patients with changes
in some cognitive domains (executive function, inhi-
bition domain, processing speed and verbal memory)
also exhibited poorer psychosocial functioning.
The linkage between clinical variables of severity
and cognitive impairment has been evaluated in sev-
eral studies in terms of age at illness onset (Bora et al.
2009), age (Arts et al. 2008 ; Gildengers et al. 2009),
number of episodes (Robinson & Ferrier, 2006), years
of stabilization and psychotic symptoms (Bora et al.
2007 ; Mann-Wrobel et al. 2011). In our study the only
relevant clinical variable related to cognitive impair-
ment was illness duration, where the longer the dur-
ation of illness the slower the processing speed. In the
same line as other studies, analysing the moderator
eﬀect of aspects of illness progression is imprecise and
not well deﬁned.
The presumable impact of psychopharmacological
treatment on cognitive dysfunction was not directly
assessed because it was not the primary aim of the
study. Medication can be a confounder (Robinson et al.
2006) and can have a negative impact on cognitive
performance ; eﬀects on psychomotor speed have been
described (Bora et al. 2009). Nonetheless, cognitive
deﬁcits are still evident in euthymic medication-free
patients (Goswami et al. 2006) and our sample was not
excessively medicated (two or fewer drug classes for
most of them), which possibly may have reduced the
eﬀect on cognition (Donaldson et al. 2003 ; Martı´nez-
Ara´n et al. 2005). Moreover, a previous study (Lo´pez-
Jaramillo et al. 2010) reported minimal eﬀects of lith-
ium on cognitive performance.T
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In spite of the growing number of studies about
neurocognition in bipolar disorder, the neurobiologi-
cal underpinnings of bipolar disorder remain un-
known (Berk et al. 2011). The present study helps to
elucidate the evolution of cognitive dysfunction in a
sample of patients with bipolar disorder. The reported
stability of cognitive impairment in the mid–late
stages of the illness may contrast with recent evidence
which supports the notion of neuroprogressive chan-
ges over time (Moorhead et al. 2007 ; Kauer-Sant’Anna
et al. 2009; Berk et al. 2011). Our results are not com-
pletely inconsistent with this hypothesis because at the
same time that the cognitive deﬁcit persists across
time in our sample, the ﬁndings also point out that a
longer duration of illness is related to progressive
changes associated with the illness itself. Future stu-
dies focused on cognition in unaﬀected ﬁrst-degree
relatives, drug-naive patients, early and late stage in
bipolar disorder or on measurement of neurobiologi-
cal biomarkers could answer the question of whether
cognitive impairment is a part of neurodevelopmental
abnormalities and clarify the pathophysiology and
the links between cognitive dysfunction and disease
progression (Dias et al. 2009 ; Kapczinski et al. 2011).
Some limitations warrant acknowledgement in the
current study. First, the sample size is relatively small
and there is a need of replication with larger samples ;
even though this is an extended follow-up of a sample
published elsewhere (Mur et al. 2008), it is worth
mentioning that the drop-out rate at 6 years later was
only 15%. An additional weakness of this extended
follow-up is that some of the key demographics were
not matched any more (e.g. estimated pre-morbid IQ
which was included as a covariate). Second, this con-
siderably homogeneous sample with low rates of re-
currence might not be representative of the majority of
bipolar patients, being biased to patients with better
outcomes (Maj et al. 1998 ; Goodwin & Vieta, 2005).
However, the good clinical outcome of our sample has
allowed us to demonstrate the continuity of neuro-
psychological deﬁcits across a long period of time.
Finally, our sample included both bipolar I and
II patients ; the sample size did not allow enough
statistical power to conduct separate analyses for the
two groups, but previous studies have reported simi-
lar rates of cognitive dysfunction and disability
in both subtypes (Rosa et al. 2010 ; Sole´ et al. 2011,
2012).
In conclusion, cognitive performance is impaired in
euthymic bipolar patients and this deﬁcit remains
stable on average over time. In spite of this, there was
individual variability where some patients displayed a
greater neuropsychological decline, which was as-
sociated with a poorer psychosocial adaptation at the
end of the follow-up. This ﬁnding endorses the fact
that longitudinal studies are needed to shedmore light
on the relative progression of cognitive impairment in
subjects with bipolar disorder (Mann-Wrobel et al.
2011). The results of the follow-up studies provide
clues about the disease process involved as they may
contribute to the development of psychosocial and
neuropsychological programmes for improving the
currently low functional recovery rates in treated bi-
polar disorder patients (Gildengers et al. 2009 ;
Martı´nez-Ara´n et al. 2011).
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